PISTELLI, MIRCO
 Distribuzione geografica
Continente #
NA - Nord America 1.058
EU - Europa 469
AS - Asia 221
SA - Sud America 44
AF - Africa 30
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 1.826
Nazione #
US - Stati Uniti d'America 1.058
IT - Italia 91
SG - Singapore 88
SE - Svezia 69
IE - Irlanda 68
CN - Cina 65
UA - Ucraina 57
RU - Federazione Russa 55
DE - Germania 48
BR - Brasile 38
HK - Hong Kong 34
CI - Costa d'Avorio 22
GB - Regno Unito 21
FI - Finlandia 18
FR - Francia 17
TR - Turchia 17
DK - Danimarca 14
KR - Corea 8
MA - Marocco 7
IN - India 5
BE - Belgio 4
AR - Argentina 3
NL - Olanda 3
AU - Australia 2
CO - Colombia 2
EU - Europa 2
JP - Giappone 2
AT - Austria 1
CZ - Repubblica Ceca 1
IQ - Iraq 1
PL - Polonia 1
PS - Palestinian Territory 1
RO - Romania 1
UY - Uruguay 1
ZA - Sudafrica 1
Totale 1.826
Città #
Chandler 170
Jacksonville 89
Ashburn 84
Fairfield 80
Dublin 67
Boardman 55
Des Moines 55
Singapore 52
New York 43
Houston 41
Woodbridge 40
Seattle 38
Wilmington 38
Hong Kong 34
Cambridge 27
Abidjan 22
Lawrence 22
Princeton 22
Ann Arbor 21
San Mateo 20
Beijing 17
Centro 15
San Diego 12
Munich 11
Turin 9
Washington 9
Moscow 8
Porto 8
The Dalles 8
Turku 8
Cagliari 6
Dallas 6
São Paulo 6
Cantu 5
Chiaravalle 5
Falls Church 5
Brussels 4
Chicago 4
Guangzhou 4
London 4
Prescot 4
Pune 4
Rome 4
Birmingham 3
Helsinki 3
Kilburn 3
Los Angeles 3
Wuhan 3
Yiwu 3
Caserta 2
Chengdu 2
Cosenza 2
Hangzhou 2
Marche 2
Nuremberg 2
Osimo 2
Phoenix 2
Qingdao 2
Recanati 2
Redmond 2
Redwood City 2
Rho 2
Richmond 2
Rio de Janeiro 2
San Francisco 2
Southwark 2
Anchieta 1
Ancona 1
Araras 1
Arqua Petrarca 1
Avant-lès-marcilly 1
Bagé 1
Baoding 1
Belo Horizonte 1
Bogotá 1
Brasília 1
Brisbane 1
Cabo Frio 1
Campinas 1
Caraguatatuba 1
Cedar Knolls 1
Cerquilho 1
Civitanova Marche 1
Clifton 1
Colombo 1
Concordia 1
Contagem 1
Dalian 1
Dangan 1
Duncan 1
Duque de Caxias 1
El Paso 1
Erbil 1
Handan 1
Hounslow 1
Iapu 1
Itaquaquecetuba 1
Jequié 1
Jinhua 1
Johannesburg 1
Totale 1.272
Nome #
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 117
Role of DCE-MR in predicting breast cancer subtypes. 110
Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO) 109
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 102
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 98
Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going? 98
Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review 96
Long‑responders to anti‑HER2 therapies: A case report and review of the literature 90
Paclitaxel and Bevacizumab in First Line-Treatment Patients with HER-2 Negative Advanced Breast Cancer: Who could Benefit? 86
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 84
Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report 82
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 81
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 78
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 76
The impact of lifestyle interventions in high‐risk early breast cancer patients: A modeling approach from a single institution experience 72
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 71
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035) 71
Expectations and psychological issues before genetic counseling: analysis of distress determinant factors 71
Adjuvant Systemic Therapy in DCIS 70
A Mixed-apprOach program To help women wIth breast cancer stay actiVE (MOTIVE program): A pilot-controlled study 62
Espressione di p-mTOR e del recettore degli androgeni nei tumori mammari triplo negativi: significato clinico e potenziali prospettive terapeutiche 59
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 57
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 33
Totale 1.873
Categoria #
all - tutte 10.736
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.736


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202037 0 0 0 0 0 0 0 0 0 0 0 37
2020/2021355 30 34 64 1 29 26 22 28 32 39 33 17
2021/2022184 12 28 4 1 2 29 11 9 17 22 17 32
2022/2023455 31 58 30 49 27 99 0 15 97 2 24 23
2023/2024242 46 3 16 17 33 70 4 16 0 3 0 34
2024/2025403 65 45 11 9 24 12 35 10 74 22 55 41
Totale 1.873